A
CPRX

AlphaQuest’s Catalyst Pharmaceutical CPRX Stock Holding History

AlphaQuest’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-130,106
Closed -$3.04M – 469
2025
Q4 		$3.04M Buy
130,106
+66,169
+103% +$1.47M 0.17% 97
2025
Q3 		$1.26M Buy
63,937
+30,817
+93% +$634K 0.08% 337
2025
Q2 		$719K Buy
33,120
+24,531
+286% +$579K 0.07% 437
2025
Q1 		$208K Sell
8,589
-35,327
-80% -$796K 0.02% 973
2024
Q4 		$917K Buy
43,916
+6,582
+18% +$141K 0.12% 267
2024
Q3 		$742K Buy
37,334
+37,231
+36,147% +$690K 0.07% 496
2024
Q2 		$1.59K Sell
103
-133
-56% -$2.07K ﹤0.01% 1364
2024
Q1 		$3.76K Buy
+236
New +$3.56K ﹤0.01% 1103

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AlphaQuest's CPRX Position: Q1 2026 in Review

AlphaQuest sold out of Catalyst Pharmaceutical (CPRX) in Q1 2026, closing a stake of 130,106 shares — an estimated $3.04M sold.

AlphaQuest first reported a position in CPRX in Q1 2024 and held it in 8 quarters. The position peaked at $3.04M in Q4 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • AlphaQuest reported no remaining Catalyst Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 130,106 Catalyst Pharmaceutical shares in Q1 2026, an estimated $3.04M.
  • AlphaQuest first reported a position in Catalyst Pharmaceutical in Q1 2024 and held it in 8 quarters.
  • AlphaQuest's Catalyst Pharmaceutical position peaked at $3.04M in Q4 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.